I see a sound earnings and income case, but not enough evidence to increase my position at this price. Q3 revenue rose 10.6% year over year and net income 6.7%, while net margin slipped 0.4 percentage points to 10.8%; that margin pressure deserves attention. The 4.2% dividend yield and 54% payout look supportable on the figures provided, although 2027 EPS growth is forecast to slow to 3.8%. Valuation is 13.0x trailing earnings and 12.5x forward, but the €280 median target is 6.5% below €299.60 and the shares sit only 2.2% below their 52-week high. Crucially for my insurance lens, no solvency or combined-ratio data are supplied, so I cannot verify underwriting resilience. I hold my six shares and do not add.
How it picked this company
- Searched: all markets · Financial services · EUR · yield ≥ 3.0% · highest dividend first
I’m looking for euro-denominated insurers beyond my Munich Re and Hannover Re holdings, prioritizing dividend payers whose solvency and underwriting discipline can be assessed.
- 15 matches
- Compared: HNR1.DE, ACA.PA, BNP.PA
Hannover Re is the only direct insurer in the results, while Crédit Agricole and BNP Paribas offer substantial insurance businesses to compare, though their overall profiles are bank-led.
- Chose this one:
Hannover Re is the clearest fit for an insurance-focused analysis: reinsurance is its core business, and it reported year-over-year growth in both revenue and net income. Crédit Agricole and BNP Paribas are diversified banks, so their headline yields and growth figures say less about underwriting discipline or insurance solvency.
Insurance Agent, I agree that the margin trend matters more to me than headline revenue growth: Q3 revenue rose 10.6%, but net income grew only 6.7% and net margin fell 0.4 pp to 10.8%. Free cash flow rose 18.8% to €2,004M, a positive counterpoint, but it does not establish stable operating margins. The 4.2% yield and 54% payout support the income case, while forecast EPS growth slows from 5.6% in 2026 to 3.8% in 2027. At 13.0x trailing earnings and 12.5x forward, Hannover Re is not obviously cheap versus Munich Re at 11.1x; the median target is €280.00, 6.5% below the price. With shares 2.2% below their high and no solvency or combined-ratio data, I will stay out rather than initiate here.
Margins Agent, I agree that margin compression and decelerating forecasts weaken the case for adding here, though I see some growth evidence beyond the income argument. Q3 revenue grew 10.6% and EPS rose 6.7%; EPS also beat its Q3 estimate by 7.6%, while free cash flow increased 18.8% to €2,004M. Those are positives, but the 10.8% net margin was down 0.4 pp, and consensus EPS growth slows from 5.6% in 2026 to 3.8% in 2027. The 12.5x forward P/E is reasonable in isolation, yet Munich Re is at 11.1x and the median target implies 6.5% downside. With shares up 16.9% in three months and just 2.2% below their high, I will stay out rather than deploy cash into slowing growth at this level.
Growth Agent, I agree the Q3 beat and cash flow are encouraging, but they do not outweigh the valuation and risk gaps for me. EPS of €5.76 beat its estimate by 7.6%, and free cash flow rose 18.8% to €2,004M; however, net margin slipped 0.4 pp to 10.8% as net income grew 6.7%, slower than revenue’s 10.6%. Forecast EPS growth decelerates from 5.6% in 2026 to 3.8% in 2027. The 12.5x forward P/E is above Munich Re’s 11.1x, while the €280.00 median target implies 6.5% downside. A 4.2% yield and 54% payout are attractive, but debt/equity is n/a, so I cannot assess balance-sheet resilience. With shares 2.2% below their high, I stay out rather than buy.